ArticleAmerican journal of cancer research2026
Integration of serological markers with O-RADS ultrasound risk stratification achieves high diagnostic accuracy for early ovarian cancer: development and validation of an interpretable model.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to enhance preoperative diagnostic accuracy for early ovarian cancer (EOC) by constructing and validating an interpretable predictive model integrating serological markers with O-RADS ultrasound risk stratification. A total of 674 patients with adnexal masses (270 EOC, 404 benign) were enrolled and randomly assigned to training (n=438) and validation (n=236) sets. Multivariate logistic regression identified cancer antigen 125 (CA125; P=0.002), human epididymal protein 4 (HE4; P=0.001), carcinoembryonic antigen (CEA; P=0.005), maximum tumor diameter (P=0.005), and Ovarian-Adnexal Reporting and Data System (O-RADS) classification (P<0.001) as independent predictors. Among individual indices, O-RADS performed best (AUC=0.854), followed by CA125 (AUC=0.783), HE4 (AUC=0.744), CEA (AUC=0.717), and maximum tumor diameter (MTD; AUC=0.696). The comprehensive model achieved an AUC of 0.969 (95% CI: 0.953-0.985) in the training set and 0.973 (95% CI: 0.952-0.994) in the validation set, with sensitivity of 0.907/0.897, specificity of 0.914/0.980, and accuracy of 0.911/0.949, significantly outperforming both the marker combination model (AUC=0.918) and individual indices (DeLong test, all P<0.05). Robust calibration was confirmed (training set: Brier score=0.062, Hosmer-Lemeshow P=0.126; validation set: Brier score=0.056, Hosmer-Lemeshow P=0.578), and decision curve analysis demonstrated positive net benefits across a wide threshold probability range. SHAP analysis identified O-RADS classification, CA125, and HE4 as the most influential predictors, with notable interactions among them. Bootstrap resampling and 5-fold cross-validation confirmed model stability. The comprehensive model demonstrated excellent diagnostic performance, robust calibration, and clinical utility, providing a reliable interpretable tool for preoperative EOC risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.